AdvisorNet Financial Inc grew its position in Allergan (NYSE:AGN) by 123.6% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,789 shares of the company’s stock after acquiring an additional 989 shares during the quarter. AdvisorNet Financial Inc’s holdings in Allergan were worth $301,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently added to or reduced their stakes in the company. Avestar Capital LLC bought a new stake in Allergan in the 4th quarter worth approximately $113,000. Focused Wealth Management Inc increased its stake in Allergan by 4,444.4% in the 4th quarter. Focused Wealth Management Inc now owns 818 shares of the company’s stock worth $134,000 after acquiring an additional 800 shares during the last quarter. Field & Main Bank bought a new stake in Allergan in the 4th quarter worth approximately $155,000. Captrust Financial Advisors bought a new stake in Allergan in the 4th quarter worth approximately $175,000. Finally, Bfsg LLC bought a new stake in Allergan in the 1st quarter worth approximately $206,000. 80.04% of the stock is currently owned by institutional investors and hedge funds.

In other Allergan news, CFO Matthew M. Walsh acquired 1,000 shares of the company’s stock in a transaction that occurred on Thursday, March 8th. The stock was bought at an average price of $153.96 per share, for a total transaction of $153,960.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Maria Teresa Hilado acquired 895 shares of the company’s stock in a transaction that occurred on Thursday, March 15th. The shares were acquired at an average price of $167.39 per share, with a total value of $149,814.05. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 8,095 shares of company stock valued at $1,258,081. 0.36% of the stock is owned by company insiders.

A number of analysts have issued reports on AGN shares. Cowen set a $255.00 price objective on Allergan and gave the stock a “buy” rating in a research note on Monday, April 16th. SunTrust Banks began coverage on Allergan in a research report on Friday, February 23rd. They set a “buy” rating and a $200.00 target price on the stock. They noted that the move was a valuation call. Vetr raised Allergan from a “sell” rating to a “hold” rating and set a $189.60 target price on the stock in a research report on Friday, January 26th. Royal Bank of Canada reissued a “buy” rating and set a $213.00 target price on shares of Allergan in a research report on Wednesday, March 14th. Finally, Morgan Stanley reissued a “buy” rating on shares of Allergan in a research report on Wednesday, January 24th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and fifteen have given a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $214.81.

Allergan opened at $160.23 on Friday, according to Marketbeat.com. Allergan has a 52-week low of $153.29 and a 52-week high of $156.87. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.10 and a quick ratio of 0.94. The firm has a market cap of $51.81 billion, a P/E ratio of 9.80, a price-to-earnings-growth ratio of 1.09 and a beta of 1.17.

Allergan (NYSE:AGN) last posted its quarterly earnings data on Monday, April 30th. The company reported $3.74 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.36 by $0.38. Allergan had a positive return on equity of 8.53% and a negative net margin of 11.94%. The company had revenue of $3.67 billion during the quarter, compared to analysts’ expectations of $3.59 billion. During the same quarter in the previous year, the business earned $3.35 EPS. Allergan’s revenue was up 2.8% compared to the same quarter last year. research analysts forecast that Allergan will post 16.03 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 15th. Investors of record on Friday, May 18th will be issued a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 1.80%. The ex-dividend date is Thursday, May 17th. Allergan’s payout ratio is currently 17.61%.

Allergan Company Profile

Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan (NYSE:AGN).

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.